197 related articles for article (PubMed ID: 15491712)
1. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.
Thatai LC; Banerjee M; Lai Z; Vaishampayan U
Urology; 2004 Oct; 64(4):738-43. PubMed ID: 15491712
[TBL] [Abstract][Full Text] [Related]
2. Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
Halabi S; Small EJ; Vogelzang NJ; Barrier RC; George SL; Gilligan TD
Urology; 2004 Aug; 64(2):212-7. PubMed ID: 15302462
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer in African-American men: outcome following radiation therapy with or without adjuvant androgen ablation.
Zagars GK; Pollack A; Pettaway CA
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):517-23. PubMed ID: 9806509
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
5. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
6. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
[TBL] [Abstract][Full Text] [Related]
7. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
[TBL] [Abstract][Full Text] [Related]
8. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
9. Association of African-American ethnic background with survival in men with metastatic prostate cancer.
Thompson I; Tangen C; Tolcher A; Crawford E; Eisenberger M; Moinpour C
J Natl Cancer Inst; 2001 Feb; 93(3):219-25. PubMed ID: 11158191
[TBL] [Abstract][Full Text] [Related]
10. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.
Johnstone PA; Kane CJ; Sun L; Wu H; Moul JW; McLeod DG; Martin DD; Kusuda L; Lance R; Douglas R; Donahue T; Beat MG; Foley J; Baldwin D; Soderdahl D; Do J; Amling CL
Radiology; 2002 Nov; 225(2):420-6. PubMed ID: 12409575
[TBL] [Abstract][Full Text] [Related]
11. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy.
Bianco FJ; Wood DP; Grignon DJ; Sakr WA; Pontes JE; Powell IJ
J Urol; 2002 Aug; 168(2):479-82. PubMed ID: 12131292
[TBL] [Abstract][Full Text] [Related]
13. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
14. Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.
Blas L; Shiota M; Yamada S; Ieiri K; Nagakawa S; Tsukahara S; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Anticancer Res; 2021 Aug; 41(8):3885-3889. PubMed ID: 34281850
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.
Loberg RD; Fielhauer JR; Pienta BA; Dresden S; Christmas P; Kalikin LM; Olson KB; Pienta KJ
Urology; 2003 Dec; 62 Suppl 1():128-33. PubMed ID: 14747050
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
Rossignol T; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
Prostate; 2021 Oct; 81(14):1091-1096. PubMed ID: 34320690
[TBL] [Abstract][Full Text] [Related]
17. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Orsola A; Planas J; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(4):209-16. PubMed ID: 16398402
[TBL] [Abstract][Full Text] [Related]
19. The impact of race on freedom from prostate-specific antigen failure in prostate cancer patients treated with definitive radiation therapy.
Young CD; Lewis P; Weinberg V; Lee TT; Coleman CW; Roach M
Semin Urol Oncol; 2000 May; 18(2):121-6. PubMed ID: 10875452
[TBL] [Abstract][Full Text] [Related]
20. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
